China Resources Boya Bio-pharmaceutical Group (300294) Q1 2026 earnings summary

Executive summary

• Revenue for Q1 2026 was ¥321.13 million, down 40.07% year-over-year due to intensified industry procurement and market competition, leading to declines in both sales volume and prices of core products.

• Net profit attributable to shareholders was ¥30.22 million, a decrease of 78.33% year-over-year.

• Cash flow from operating activities was negative at ¥127.23 million, down 202.07% year-over-year, mainly due to lower collections.

Financial highlights

• Operating income: ¥321.13 million, down 40.07% year-over-year.

• Net profit attributable to shareholders: ¥30.22 million, down 78.33% year-over-year.

• Net profit excluding non-recurring items: ¥20.32 million, down 80.13% year-over-year.

• Basic and diluted EPS: ¥0.06, down 78.57% year-over-year.

• Total assets at period end: ¥8.41 billion, down 2.55% from year-end 2025.

Outlook and guidance

• Industry-wide procurement and increased competition are expected to continue impacting sales and pricing of core products.